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Background: Variable response to clopidogrel, manifest as suboptimal platelet inhibition, has been associated with greater risk for 
atherothrombotic events after percutaneous coronary intervention (PCI). Cilostazol, as an adjunctive antiplatelet agent to dual antiplatelet therapy 
with aspirin and clopidogrel (DAPT), has been shown to reduce cardiovascular events after PCI but its effect on platelet reactivity is not well defined.
Methods: We performed a MEDLINE/EMBASE and CENTRAL search with the terms “cilostazol” and “randomized clinical trial” evaluating triple 
therapy (TAPT) with cilostazol versus DAPT after PCI with platelet reactivity outcomes. The primary outcome was the difference in on-treatment in 
platelet reactivity unit (PRU) with TAPT vs DAPT after treatment. Secondary outcomes of rate of high (PRU>235) on treatment platelet reactivity (HPR) 
and percent platelet inhibition were evaluated.
Results: 10 trials with 1,679 patients met our inclusion criteria. TAPT was associated with a significantly lower PRU value compared with DAPT 
(Figure). Furthermore, TAPT significantly reduced the risk of HPR (RR 0.33, 95% CI 0.22 - 0.51, p value <0.000001), and achieved greater platelet 
inhibition by 13.28% (CI 9.88 - 16.69, p value <0.000001) when compared with DAPT.
Conclusions: TAPT with cilostazol in patients undergoing PCI results in significantly lower on-treatment PRU level, lower rate of HPR and greater 
percent platelet inhibition compared to DAPT.
